Daniel Mark Ledger

Daniel Mark Ledger is a notable inventor based in Bradford, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of innovative formulations and compositions. With a total of six patents to his name, Ledger's work has the potential to impact various medical treatments.

Latest Patents

Ledger's latest patents include a formulation of inhalable particles, which consists of a powder formulation comprising particles of an antimuscarinic agent. These particles are obtainable by supercritical anti-solvent (SAS) precipitation and have specific size characteristics, with a Dof of 4 µm or less and a Dof of 10 µm or less. Additionally, he has developed crystal forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride, which are characterized and disclosed in his patents. These polymorphic forms and their metabolites are particularly relevant for the treatment of Alzheimer's disease.

Career Highlights

Throughout his career, Ledger has worked with several companies, including Crystec Ltd and Anavex Life Sciences Corporation. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Ledger has collaborated with notable coworkers such as Linda Sharon Daintree and Peter York. These partnerships have likely enhanced his research and development efforts, leading to innovative solutions in the field.

Conclusion

Daniel Mark Ledger's contributions to pharmaceutical innovations demonstrate his commitment to advancing medical science. His patents reflect a deep understanding of complex formulations and their applications in treating significant health conditions.

This text is generated by artificial intelligence and may not be accurate.